Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The employee stock option has a 10-year term.

Rhea-AI Summary

Taysha Gene Therapies (TSHA) granted equity awards to four new employees on October 1, 2026, as inducements to enter employment.

The awards comprise restricted stock units (RSUs) representing 384,000 common shares and an option to purchase 92,400 common shares under the 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). RSUs are awards that vest into shares. They vest in four equal annual installments beginning on the first anniversary of the vesting commencement date. The option's $4.74 exercise price equals the closing share price on the grant date. It vests over four years: 25% on the first anniversary of the vesting commencement date and the remaining 75% monthly over the next 36 months. Both awards require continued service at each vesting date.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.RSUs representing 384,000 common shares create potential dilution as the employee awards vest.
• Minor point. Forward-looking: it has not happened yet and may not happen.Option to purchase 92,400 common shares at $4.74 creates potential dilution upon exercise.

Key Figures

RSU shares: 384,000 shares Option shares: 92,400 shares Option exercise price: $4.74 +3 more

RSU shares

384,000 shares

Granted to four new employees

Option shares

92,400 shares

Granted to four new employees

Option exercise price

$4.74

Equal to the closing price on the grant date

Option term

10 years

Stock option award

RSU vesting

Four equal annual installments

Beginning on the first anniversary of the vesting commencement date; continued service required

Option vesting

25% on the first anniversary; remaining 75% in equal monthly installments over 36 months

Continued service required

Key Terms

restricted stock units, adeno-associated virus, monogenic diseases, central nervous system

4 terms

restricted stock units financial

"granted four new employees restricted stock units (RSUs) representing 384,000 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

adeno-associated virus medical

"advancing adeno-associated virus (AAV)-based gene therapies"

Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.

monogenic diseases medical

"gene therapies for severe monogenic diseases of the central nervous system"

A monogenic disease is a medical condition caused by a harmful change in a single gene, where that single faulty instruction is enough to produce symptoms. For investors, these diseases matter because their clear genetic cause can make it easier for drug developers to design targeted therapies, diagnostics, or gene therapies, creating distinct clinical pathways, regulatory considerations, and potentially more predictable commercial opportunities—like fixing one broken line of code in a program.

central nervous system medical

"severe monogenic diseases of the central nervous system (CNS)"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date. The stock option has an exercise price of $4.74 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
investors@tayshagtx.com  

Media Contact:
media@tayshagtx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Taysha Gene Therapies grant to new employees on October 1, 2026?

Taysha granted four new employees RSUs representing 384,000 common shares and an option to purchase 92,400 common shares. The awards were employment inducements under the 2023 Inducement Plan. The option's exercise price is $4.74, equal to the closing share price on the grant date.

How do Taysha Gene Therapies' October 1, 2026 employee equity awards vest?

The RSUs vest in four equal annual installments, while the option vests 25% after one year and the remaining 75% in equal monthly installments over the following 36 months. Both schedules start from the award's vesting commencement date and require continued service at each vesting date.